Equities
Health CareHealth Care Equipment & Services
  • Price (USD)113.52
  • Today's Change1.14 / 1.01%
  • Shares traded4.18m
  • 1 Year change18.87%
  • Beta0.6050
Data delayed at least 15 minutes, as of Dec 13 2019 23:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

  • Revenue in USD (TTM)30.89bn
  • Net income in USD4.62bn
  • Incorporated2014
  • Employees90.07k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MDT:NYQ since
announced
Transaction
value
Titan Spine IncDeal completed09 May 201909 May 2019Deal completed27.55%--
Advanced Cardiac Therapeutics IncAnnounced24 Jan 201924 Jan 2019Announced30.24%--
Data delayed at least 15 minutes, as of Dec 13 2019 23:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zimmer Biomet Holdings Inc7.93bn-81.90m30.46bn19.00k--2.5233.003.84-0.4475-0.488238.5358.760.3190.94956.57417,236.80-0.33851.26-0.38651.3972.5670.96-1.063.930.54034.910.408566.571.6611.40-168.51--8.433.71
Baxter International Inc11.08bn1.39bn42.87bn50.00k32.135.4819.663.872.612.9720.8415.310.64943.766.04221,600.008.148.539.6210.8642.6542.2812.5416.272.1043.420.397132.915.363.408.7135.20-14.89-17.59
Edwards Lifesciences Corp4.15bn819.70m48.52bn12.80k60.2112.7253.6211.693.863.6519.5718.300.69631.788.36324,343.8013.7516.0316.5819.0774.4074.1919.7423.372.74--0.13480.008.3712.72-15.9213.6617.03--
Boston Scientific Corporation10.39bn1.03bn62.85bn32.00k61.536.4831.466.050.73290.77417.386.960.4412.266.16324,750.004.382.815.463.5070.6970.489.936.080.77133.400.52890.008.576.5866.22--11.05--
Intuitive Surgical, Inc.4.25bn1.29bn66.99bn5.53k53.798.6345.5715.7710.7811.0135.5767.140.51642.736.97768,463.9015.6014.2817.3415.9769.4568.8030.2027.414.01--0.000.0018.6710.4614.1310.9612.37--
Becton Dickinson and Co17.29bn1.03bn72.68bn70.09k71.523.4522.144.203.763.9463.2177.950.32723.587.41246,658.002.242.792.553.2247.9347.276.847.200.72244.760.479172.798.1815.4129.16-2.737.947.16
Stryker Corporation14.55bn1.87bn75.97bn36.00k41.286.1728.935.224.929.0238.3132.900.5971.626.45404,138.907.667.639.189.3965.7066.2412.8313.071.35--0.405939.869.308.567.6114.6624.0112.14
Thermo Fisher Scientific Inc.25.22bn3.56bn128.52bn70.00k36.374.3822.095.108.818.8962.4373.210.45114.456.12360,285.706.374.947.075.5844.4845.0914.1211.691.238.550.367510.8016.4513.2225.6219.0221.831.92
Medtronic PLC30.89bn4.62bn152.16bn90.07k33.203.0120.784.933.423.4522.8537.730.34482.405.21342,962.805.194.395.734.9069.6369.2615.0714.552.2810.950.335754.462.0212.44-13.808.6623.4212.30
Abbott Laboratories31.36bn3.29bn152.71bn103.00k46.684.8024.194.871.851.8517.6317.990.44743.175.85304,417.504.703.635.654.3758.6456.3910.508.091.127.040.373686.5611.649.2435.914.394.0114.87
Data as of Dec 13 2019. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD

Institutional shareholders

34.66%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2019111.62m8.33%
Wellington Management Co. LLPas of 30 Sep 201973.09m5.45%
BlackRock Fund Advisorsas of 30 Sep 201966.84m4.99%
SSgA Funds Management, Inc.as of 30 Sep 201957.30m4.28%
Massachusetts Financial Services Co.as of 30 Sep 201954.64m4.08%
Lazard Asset Management LLCas of 30 Sep 201928.16m2.10%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 201922.73m1.70%
Geode Capital Management LLCas of 30 Sep 201918.46m1.38%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 201916.80m1.25%
Columbia Management Investment Advisers LLCas of 30 Sep 201914.94m1.12%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.